Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Tetradecylthioacetic acid attenuates dyslipidaemia in male patients with type 2 diabetes mellitus, possibly by dual PPAR-alpha/delta activation and increased mitochondrial fatty acid oxidation.

Løvås K, Røst TH, Skorve J, Ulvik RJ, Gudbrandsen OA, Bohov P, Wensaas AJ, Rustan AC, Berge RK, Husebye ES.

Diabetes Obes Metab. 2009 Apr;11(4):304-14. doi: 10.1111/j.1463-1326.2008.00958.x.

PMID:
19267708
2.

Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.

Bajaj M, Suraamornkul S, Hardies LJ, Glass L, Musi N, DeFronzo RA.

Diabetologia. 2007 Aug;50(8):1723-31. Epub 2007 May 23.

PMID:
17520238
3.

Antiinflammatory effects of tetradecylthioacetic acid involve both peroxisome proliferator-activated receptor alpha-dependent and -independent pathways.

Dyrøy E, Yndestad A, Ueland T, Halvorsen B, Damås JK, Aukrust P, Berge RK.

Arterioscler Thromb Vasc Biol. 2005 Jul;25(7):1364-9. Epub 2005 May 26.

4.

The metabolic syndrome and the hepatic fatty acid drainage hypothesis.

Berge RK, Tronstad KJ, Berge K, Rost TH, Wergedahl H, Gudbrandsen OA, Skorve J.

Biochimie. 2005 Jan;87(1):15-20. Review.

PMID:
15733731
5.

The effect of dual PPAR alpha/gamma stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients.

Seber S, Ucak S, Basat O, Altuntas Y.

Diabetes Res Clin Pract. 2006 Jan;71(1):52-8. Epub 2005 Jul 11.

PMID:
16009445
6.

PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes.

Seo YS, Kim JH, Jo NY, Choi KM, Baik SH, Park JJ, Kim JS, Byun KS, Bak YT, Lee CH, Kim A, Yeon JE.

J Gastroenterol Hepatol. 2008 Jan;23(1):102-9. doi: 10.1111/j.1440-1746.2006.04819.x. Erratum in: J Gastroenterol Hepatol. 2009 May;24(5):932. J Gastroenterol Hepatol. 2009 Jul;24(7):1310.

PMID:
18171348
7.

Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial.

Goldstein BJ, Rosenstock J, Anzalone D, Tou C, Ohman KP.

Curr Med Res Opin. 2006 Dec;22(12):2575-90.

PMID:
17166340
8.

A dual PPAR alpha/gamma agonist increases adiponectin and improves plasma lipid profiles in healthy subjects.

Decochez K, Rippley RK, Miller JL, De Smet M, Yan KX, Matthijs Z, Riffel KA, Song H, Zhu H, Maynor HO, Tanaka W, Johnson-Levonas AO, Davies MJ, Gottesdiener KM, Keymeulen B, Wagner JA.

Drugs R D. 2006;7(2):99-110.

PMID:
16542056
9.
10.

Modulation of rat liver apolipoprotein gene expression and serum lipid levels by tetradecylthioacetic acid (TTA) via PPARalpha activation.

Raspé E, Madsen L, Lefebvre AM, Leitersdorf I, Gelman L, Peinado-Onsurbe J, Dallongeville J, Fruchart JC, Berge R, Staels B.

J Lipid Res. 1999 Nov;40(11):2099-110.

11.

Lipid-lowering and anti-inflammatory effects of tetradecylthioacetic acid in HIV-infected patients on highly active antiretroviral therapy.

Fredriksen J, Ueland T, Dyrøy E, Halvorsen B, Melby K, Melbye L, Skalhegg BS, Bohov P, Skorve J, Berge RK, Aukrust P, Frøland SS.

Eur J Clin Invest. 2004 Oct;34(10):709-15.

PMID:
15473896
12.

Role of AMP kinase and PPARdelta in the regulation of lipid and glucose metabolism in human skeletal muscle.

Krämer DK, Al-Khalili L, Guigas B, Leng Y, Garcia-Roves PM, Krook A.

J Biol Chem. 2007 Jul 6;282(27):19313-20. Epub 2007 May 11.

13.

Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes.

Buse JB, Rubin CJ, Frederich R, Viraswami-Appanna K, Lin KC, Montoro R, Shockey G, Davidson JA.

Clin Ther. 2005 Aug;27(8):1181-95.

PMID:
16199244
14.

A selective peroxisome proliferator-activated receptor alpha agonist, CP-900691, improves plasma lipids, lipoproteins, and glycemic control in diabetic monkeys.

Wagner JD, Shadoan MK, Zhang L, Ward GM, Royer LJ, Kavanagh K, Francone OL, Auerbach BJ, Harwood HJ Jr.

J Pharmacol Exp Ther. 2010 Jun;333(3):844-53. doi: 10.1124/jpet.110.166736. Epub 2010 Feb 26.

15.

Activation of PPAR-delta in isolated rat skeletal muscle switches fuel preference from glucose to fatty acids.

Brunmair B, Staniek K, Dörig J, Szöcs Z, Stadlbauer K, Marian V, Gras F, Anderwald C, Nohl H, Waldhäusl W, Fürnsinn C.

Diabetologia. 2006 Nov;49(11):2713-22. Epub 2006 Sep 8.

PMID:
16960684
16.
17.
18.

Efficacy and safety of a potent and selective peroxisome proliferator activated receptor alpha agonist in subjects with dyslipidemia and type 2 diabetes mellitus.

Terra SG, Francone OL, Contant CF, Gao X, Lewin AJ, Nguyen TT.

Am J Cardiol. 2008 Aug 15;102(4):434-9. doi: 10.1016/j.amjcard.2008.03.076. Epub 2008 May 22.

PMID:
18678301
19.

Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.

Fruchart JC, Duriez P.

Drugs Today (Barc). 2006 Jan;42(1):39-64. Review.

PMID:
16511610
20.

Supplemental Content

Support Center